The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir …
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir …
JA Pandit, JM Radin, DC Chiang, EG Spencer… - 2023 - cabidigitallibrary.org
Background: The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With …
JA Pandit, JM Radin, DC Chiang… - Clinical Infectious …, 2023 - academic.oup.com
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus …
JA Pandit, JM Radin, D Chiang… - … Diseases: an Official …, 2023 - europepmc.org
The uptake of nirmatrelvir plus ritonavir (NPR) in patients with COVID-19 has been limited by
concerns around the rebound phenomenon despite the scarcity of evidence around its …
concerns around the rebound phenomenon despite the scarcity of evidence around its …
[HTML][HTML] The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With …
JA Pandit, JM Radin, DC Chiang… - … Diseases: An Official …, 2023 - ncbi.nlm.nih.gov
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With …
JA Pandit, JM Radin, DC Chiang… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …